A study at Shanghai Proton and Heavy Ion Center evaluated proton radiotherapy for IDH-mutant astrocytoma and oligodendroma. The 12/24-month progression-free survival rate was 97.6%/78.4%, while the 12/24-month overall survival rate was 100%/91%. There were no grade 3 or higher acute toxicities. In terms of late toxicity, grade 3 radionecrosis was seen in 1 of 52 patients. The authors conclude that proton radiotherapy resulted in favorable outcomes with acceptable adverse events in patients with IDH-mutant diffuse glioma.
